 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. News Gilead Sciences First-Quarter Profits Driven by Increase in Sales of Antiretroviral VireadApril 26, 2004 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Foster City, Calif.-based Gilead Sciences on Thursday announced first-quarter 2004 net profits of $114.4 million, up from a net loss of $438.1 million during the same quarter last year, an increase largely driven by sales of its antiretroviral drug Viread, Reuters reports (Berkrot/Pierson, Reuters, 4/22). Gilead -- which manufactures Viread, the fifth best-selling antiretroviral drug in the United States -- in July 2003 launched a second antiretroviral drug, Emtriva, and is developing a once-daily combination pill to compete with industry leader GlaxoSmithKline's top-selling Combivir (Kaiser Daily HIV/AIDS Report, 10/30/03). Sales of Viread increased 80% to $193.1 million during the first quarter of 2004, and the company raised its yearly sales forecast for the drug to between $725 million and $775 million. In addition, sales of Emtriva reached $12 million in the first quarter. The company also said it plans to start clinical trials of a new protease inhibitor, according to Reuters (Reuters, 4/22). Back to other news for April 26, 2004
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!  This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
